SNYDER DAVID S 4

What Happened
CFO David S. Snyder received a grant/award of 140,041 derivative shares for Coya Therapeutics (COYA) on January 22, 2026. The filing reports a price of $0.00 and a total reported value of $0; the award is a derivative grant (see footnote) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-22; Filing date: 2026-01-26 (appears timely — within the typical 2 business‑day Form 4 window).
• Reported amount: 140,041 derivative shares; reported price: $0.00; reported total value: $0.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The shares underlying the option will vest in monthly installments over the next 36 months, subject to continued service; vesting accelerates upon a change in control per the company’s 2021 Equity Incentive Plan (amended Nov 17, 2022).
• Transaction code: A = Award/Grant (derivative).

Context
This was an equity award (derivative/option-style) subject to multi-year vesting — not an immediate purchase or sale. Such grants are common as compensation and do not by themselves indicate the insider buying or selling stock in the open market. The key investor takeaway is the award increases potential future insider ownership if vesting conditions are met.